Alzheimer’s Drug with Modest Benefits Gets Green Light from FDA Advisers
The drug donanemab slows progression of symptoms in people with early stages of Alzheimer’s disease, but questions linger about the durability of its effect
The drug donanemab slows progression of symptoms in people with early stages of Alzheimer’s disease, but questions linger about the durability of its effect
What's Your Reaction?
SIN
ScienceX Information Network (SIN) | ScienceX Innovations
